

Rabbit Anti-EGFR (E746-A750del Specific) [MD26R]: RM0329RTU7

Intended Use: For Research Use Only

Description: Two types of mutations account for approximately 90% of mutated cases: a specific point mutation, L858R, which occurs in exon 21 and short in-frame deletions in exon 19. A common lesion in exon 19 is the deletion of E746-A750, although other variants occur. IHC-based EGFR E746-A750del specific antibody is designed to detect deletion of E746-A750 in exon 19. Deletion in exon 19 is associated with response of non-small cell lung carcinoma (NSCLC) to gefitinib or erlotinib monotherapy.

Specifications:


Clone: MD26R
Source: Rabbit
Isotype: IgG
Reactivity: Human
Localization: Membrane
Formulation: Antibody in PBS pH7.4, containing BSA, glycerol, and < 0.09% sodium azide (NaN₃).
Storage: Store at 2°- 8°C.
Applications: IHC, Flow Cyt., IF, IP, WB
Package:

Description	Catalog No.	Size
EGFR (E746-A750del Specific) Prediluted	RM0329RTU7	7 ml

IHC Procedure*:

Positive Control Tissue: Lung carcinoma E746-A750del specific
Concentrated Dilution: Prediluted
Pretreatment: EDTA pH8.0, 15 minutes using Pressure Cooker, or 30-60 minutes using water bath at 95°-99°C
Incubation Time and Temp: 30-60 minutes @ RT
Detection: Refer to the detection system manual

* Result should be confirmed by an established diagnostic procedure.



FFPE human lung carcinoma stained with anti-EGFR (E746-A750del specific) using DAB

References:

1. Complex mutations subpopulations of deletions at exon 19 of EGFR in NSCLC revealed by next generation sequencing: potential clinical implications. Marchetti, A., et al. PLoS ONE on 31 July 2012.
2. Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells. Huang, W. C., Chen, Y. J., et al. Journal of Biological Chemistry on 10 June 2011.
3. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. Kato, Y., et al. Journal of Thoracic Oncology, 1 October 2010.